Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

PTGX stock hub

Protagonist Therapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

PTGXis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

6.4B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

PTGX

In the news

Latest news · PTGX

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E23.9

P25 12.6P50 18.3P75 33.7

Trailing P/En/a

P25 15P50 23.3P75 38.5

ROE-17.1

P25 -106.6P50 -46.9P75 -3.1

ROIC-162.7

P25 -63.1P50 -27.5P75 -0

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All PTGX market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

214

Groups with data

Currency

USD

Showing 214 of 214 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001377121
Company name	Protagonist Therapeutics, Inc.
Country	United States
Country code	US
Cusip	74366E102
Employees	132
Employees Change	6%
Employees Change Percent	4.76
Enterprise value	$5.8B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2016-08-11
Isin	US74366E1029
Last refreshed	2026-05-10
Market cap	$6.4B
Market cap category	Mid-Cap
Price	$99.36
Price currency	USD
Rev Per Employee	561,083.33x
Sector	Healthcare
Sic	2834
Symbol	PTGX
Website	https://www.protagonist-inc.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-1.8%
EV Sales Forward	13.45x
EV/Sales	78.03x
FCF yield	-1.85%
Forward P/E	23.89x
P/B ratio	9.74x
P/S ratio	86.28x
PS Forward	14.87x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-192.36%
EBITDA Margin	-190.4%
Gross margin	100%
Gross Profit	$74.1M
Gross Profit Growth	-64.36%
Gross Profit Growth Q	99.03%
Gross Profit Growth3 Y	341.78%
Gross Profit Growth5 Y	18.9%
Net Income	$-114.7M
Net Income Growth Quarters	1%
Net Income Growth Years	0%
Pretax Margin	-155.78%
Profit Margin	-154.88%
Profit Per Employee	$-869,023
ROA	-12.37
Roa5y	-11.12
ROCE	-21.49
ROE	-17.06
Roe5y	-17.42
ROIC	-162.7

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	130.72%
Cagr3y	58.79%
Cagr5y	27.77%
EPS Growth Quarters	1
EPS Growth Years	0
Revenue Growth	-64.36x
Revenue Growth Q	99.03x
Revenue Growth Quarters	1x
Revenue Growth Years	0x
Revenue Growth3 Y	341.78x
Revenue Growth5 Y	18.9x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.1
Assets	$697.5M
Cash	$547.8M
Current Assets	$613.5M
Current Liabilities	$34.5M
Debt	$9.8M
Debt Equity	$0.01
Equity	$655.5M
Liabilities	$42M
Long Term Assets	$84M
Long Term Liabilities	$7.4M
Net Cash	$610.6M
Net Cash By Market Cap	$9.55
Net Cash Growth	-11.06%
Net Debt Equity	$-0.93
Tangible Book Value	$655.5M
Tangible Book Value Per Share	$10.21
WACC	14.58

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	17.76
Net Working Capital	$33.5M
Quick ratio	17.51
Working Capital	$578.9M
Working Capital Turnover	$0.13

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	1.26%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	130.59%
200-day SMA	80.88
3Y total return	300.48%
50-day SMA	99.76
50-day SMA vs 200-day SMA	50over200
5Y total return	240.51%
All Time High	107.8
All Time High Change	-7.86%
All Time High Date	2026-04-01
All Time Low	4.47
All Time Low Change	2,122.82%
All Time Low Date	2019-12-03
ATR	4.21
Beta	1.88
Beta1y	-0.51
Beta2y	0.1
Ch YTD	13.76
High	100.2
High52	107.8
High52 Date	2026-04-01
High52ch	-7.86%
Low	97
Low52	41.6
Low52 Date	2025-05-08
Low52ch	138.85%
Ma50ch	-0.4%
Premarket Change Percent	0.63
Premarket Price	$99.47
Premarket Volume	3,510
Price vs 200-day SMA	22.85%
RSI	47.87
RSI Monthly	74.9
RSI Weekly	63.34
Sharpe ratio	1.84x
Sortino ratio	3.61
Total Return	1.26%
Tr YTD	13.76
Tr1m	-4.23%
Tr1w	1.01%
Tr3m	17.6%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	13
Analyst Count Top	8
Analyst Price Target Top	$116
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.65
Earnings Revenue Estimate	14,018,576x
Earnings Revenue Estimate Growth	-50.5x
Operating Income	$-142.5M
Operating margin	-192.4
Price target	$113
Price Target Change	$13.35
Price Target Change Top	$16.88

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	52,684,476%
Float Percent	81.92%
Shares Insiders	0.62%
Shares Institutions	96.79%
Shares Out	64,311,373
Shares Qo Q	10.09%
Shares Yo Y	-1.26%
Short Float	15.94%
Short Ratio	8.77
Short Shares	13.06

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-164.6M
Average Volume	668,445.1x
Bv Per Share	10.21
CAPEX	$-1.3M
Ch1m	-4.23
Ch1w	1.01
Ch1y	130.6
Ch3m	17.6
Ch3y	300.5
Ch5y	240.5
Ch6m	24.92
Change	0.52%
Change From Open	0.86
Close	98.85
Days Gap	-0.34
Depreciation Amortization	1,448,000
Dollar Volume	50,173,123.7
Earnings Date	2026-05-05
Earnings Time	amc
EBIT	$-142.5M
EBITDA	$-141M
EPS	$-1.79
F Score	1
FCF	$-117.9M
FCF EV Yield	-2.04x
FCF Per Share	$-1.83
Financing CF	34,795,000
Fiscal Year End	December
Founded	2,006
Income Tax	$-664,000
Investing CF	135,962,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-05
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-25
Ma150	88.42
Ma150ch	12.37%
Ma20	101.7
Ma20ch	-2.27%
Net CF	54,122,000
Next Earnings Date	2026-08-05
Open	98.51
Optionable	Yes
Position In Range	74.92
Post Close	99.36
Postmarket Change Percent	1.45
Postmarket Price	$101
Ppne	11,168,000
Pre Close	98.85
Price Date	2026-05-08
Ptbv Ratio	9.75
Relative Volume	0.76x
Revenue	74,063,000x
SBC By Revenue	63.04x
Share Based Comp	46,691,000
Tax By Revenue	-0.9x
Tr6m	24.92%
Us State	California
Volume	504,963
Z Score	60.84

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does PTGX pay a dividend?

Capital-return profile for this ticker.

Performance

PTGX stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns PTGX?

Insider, institutional, and short-interest positioning.

Institutional ownership

+96.8%

Float: +81.9% of shares outstanding

Insider ownership

+0.6%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

PTGX momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

47.9

Neutral momentum band

Price vs 200-day MA

+22.8%

50/200-day relationship not available

Beta (5Y)

1.88

More volatile than the market

Sharpe ratio

1.84

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About PTGX

Hub-level FAQ points readers to the deeper analysis pages.

What is the current PTGX stock rating?

Protagonist Therapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full PTGX analysis?

The full report lives at /stocks/PTGX/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for PTGX?

The latest report frames PTGX around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the PTGX page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.